Goldman Sachs’s Blueprint Medicines BPMC Stock Holding History

Goldman Sachs’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-891,287	Closed	-$114M	–	6346
2025 Q2	$114M	Sell	891,287 -35,381	-4%	-$3.67M	0.02%	817
2025 Q1	$82M	Sell	926,668 -119,867	-11%	-$11.7M	0.01%	891
2024 Q4	$91.3M	Buy	1,046,535 +324,903	+45%	+$29.8M	0.01%	856
2024 Q3	$66.8M	Sell	721,632 -17,606	-2%	-$1.75M	0.01%	1024
2024 Q2	$79.7M	Buy	739,238 +172,584	+30%	+$17.3M	0.01%	908
2024 Q1	$53.8M	Sell	566,654 -11,401	-2%	-$978K	0.01%	1124
2023 Q4	$53.3M	Buy	578,055 +233,337	+68%	+$15.1M	0.01%	1141
2023 Q3	$17.3M	Sell	344,718 -44,638	-11%	-$2.39M	﹤0.01%	1934
2023 Q2	$24.6M	Buy	389,356 +54,765	+16%	+$2.98M	0.01%	1674
2023 Q1	$15.1M	Buy	334,591 +17,329	+5%	+$781K	﹤0.01%	2058
2022 Q4	$13.9M	Sell	317,262 -5,288	-2%	-$254K	﹤0.01%	2279
2022 Q3	$21.3M	Buy	322,550 +64,406	+25%	+$4.14M	0.01%	1807
2022 Q2	$13M	Sell	258,144 -48,632	-16%	-$2.85M	﹤0.01%	2263
2022 Q1	$19.6M	Sell	306,776 -93,695	-23%	-$6.73M	﹤0.01%	2053
2021 Q4	$42.9M	Sell	400,471 -212,594	-35%	-$22.2M	0.01%	1472
2021 Q3	$63M	Buy	613,065 +62,685	+11%	+$5.84M	0.01%	1087
2021 Q2	$48.4M	Buy	550,380 +62,167	+13%	+$5.7M	0.01%	1288
2021 Q1	$47.5M	Sell	488,213 -81,265	-14%	-$8.11M	0.01%	1207
2020 Q4	$63.9M	Buy	569,478 +54,105	+10%	+$5.7M	0.02%	926
2020 Q3	$47.8M	Sell	515,373 -8,462	-2%	-$652K	0.01%	1036
2020 Q2	$40.9M	Buy	523,835 +8,858	+2%	+$599K	0.01%	1119
2020 Q1	$30.1M	Buy	514,977 +160,912	+45%	+$10.4M	0.01%	1210
2019 Q4	$28.4M	Sell	354,065 -11,408	-3%	-$854K	0.01%	1574
2019 Q3	$26.9M	Buy	365,473 +13,384	+4%	+$1.16M	0.01%	1570
2019 Q2	$33.2M	Sell	352,089 -49,729	-12%	-$4.1M	0.01%	1457
2019 Q1	$32.2M	Buy	401,818 +81,458	+25%	+$6.02M	0.01%	1468
2018 Q4	$17.3M	Sell	320,360 -99,119	-24%	-$6.02M	0.01%	1925
2018 Q3	$32.7M	Buy	419,479 +64,806	+18%	+$4.5M	0.01%	1540
2018 Q2	$22.5M	Buy	354,673 +80,265	+29%	+$6.39M	0.01%	1792
2018 Q1	$25.2M	Buy	274,408 +109,969	+67%	+$9.48M	0.01%	1660
2017 Q4	$12.4M	Sell	164,439 -61,034	-27%	-$4.29M	﹤0.01%	2289
2017 Q3	$15.7M	Buy	225,473 +14,681	+7%	+$785K	﹤0.01%	2193
2017 Q2	$10.7M	Sell	210,792 -142,764	-40%	-$6.06M	﹤0.01%	2471
2017 Q1	$14.1M	Buy	353,556 +260,247	+279%	+$9.32M	﹤0.01%	2150
2016 Q4	$2.62M	Buy	93,309 +61,672	+195%	+$1.86M	﹤0.01%	3598
2016 Q3	$940K	Buy	+31,637	New	+$786K	﹤0.01%	4459
2016 Q2	–	Sell	-47,238	Closed	-$853K	–	7028
2016 Q1	$853K	Sell	47,238 -46,481	-50%	-$806K	﹤0.01%	4209
2015 Q4	$2.47M	Buy	93,719 +84,099	+874%	+$1.89M	﹤0.01%	3445
2015 Q3	$205K	Sell	9,620 -9,247	-49%	-$256K	﹤0.01%	6001
2015 Q2	$500K	Buy	+18,867	New	+$539K	﹤0.01%	5218

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's BPMC Position: Q3 2025 in Review

Goldman Sachs sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 891,287 shares — an estimated $114M sold.

Goldman Sachs first reported a position in BPMC in Q2 2015 and held it in 40 quarters. The position peaked at $114M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Goldman Sachs reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Goldman Sachs sold 891,287 Blueprint Medicines shares in Q3 2025, an estimated $114M.
Goldman Sachs first reported a position in Blueprint Medicines in Q2 2015 and held it in 40 quarters.
Goldman Sachs's Blueprint Medicines position peaked at $114M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.